血压对阿尔茨海默病生理机制的影响研究
Study on the Effect of Blood Pressure on the Physiological Mechanism of Alzheimer’s Disease
DOI: 10.12677/ACM.2022.12111451, PDF,    科研立项经费支持
作者: 许斯贤*, 杨亿馨, 陈紫霞, 杨颖瑜, 王筠柠:宁德师范学院医学院,福建 宁德;苏裕盛#:宁德师范学院医学院,福建 宁德;宁德师范学院毒物与药物毒理学重点实验室,福建 宁德
关键词: 阿尔茨海默病血压tau蛋白Alzheimer’s Disease Blood Pressure Tau Protein
摘要: 阿尔茨海默病(Alzheimer’s Disease, AD)是最常见的散发性神经退行性疾病,其特点为记忆力减退,并迅速发展为人格改变和语言问题等症状,导致丧失进行日常活动的能力,最终致使个体死亡。尽管在了解疾病过程方面取得了重大进展,但确切的病理生理机制仍然难以捉摸。在治疗方面并没有存在能与之直接对应关系的药物且临床效果不显著,因此开展非药物干预措施来改善认知功能以及延缓AD的进程至关重要,同时做到AD的早发现早诊断早治疗。AD的发病机制是淀粉样蛋白β肽(amyloid-protein β, Aβ)的细胞外斑块沉积过多,微管相关蛋白tau以细丝形式在神经元内聚集,神经炎症的诱发和自身抗体侵入脑组织等,这些异常的生理现象均有使认知功能和记忆功能下降。根据目前相关权威的研究表明,血压的异常是AD常见的可预防危险因素之一,保持血压在正常区间内动态平衡与AD发生风险的降低存在一定的关系。研究表明通过控制血压动态平衡可以清除血压造成的神经炎症、减少脑血管意外和高血压的发生率、控制舒张压和收缩压的水平以及保护血脑屏障,这些方面在预防和改善认知功能上具有非常重要的作用。因此,控制血压动态平衡被认为是临床前、中和后期对AD的治疗与预防措施,定期进行血压检测具有一定程度的推广意义。
Abstract: Alzheimer’s Disease (AD) is the most common sporadic neurodegenerative disease. It is character-ized by memory loss and rapidly develops into personality changes, language problems and other symptoms, resulting in the loss of the ability to carry out daily activities and ultimately individual death. Although significant progress has been made in understanding the disease process, the exact pathophysiological mechanism remains elusive. In terms of treatment, there is no drug that can di-rectly correspond to it and the clinical effect is not significant. Therefore, it is essential to carry out non-drug interventions to improve cognitive function and delay the process of AD, and at the same time, it is important to achieve early detection, early diagnosis and early treatment of AD. The pathogenesis of AD is amyloid protein β (Aβ). Excessive extracellular plaque deposition, microtu-bule associated protein tau aggregation in the form of filaments in neurons, the induction of neu-roinflammation and the invasion of autoantibodies into brain tissue, etc., these abnormal physio-logical phenomena have reduced cognitive and memory functions. According to the current re-search of relevant authorities, abnormal blood pressure is one of the common preventable risk fac-tors of AD, and there is a certain relationship between maintaining the dynamic balance of blood pressure within the normal range and reducing the risk of AD. Research shows that controlling the dynamic balance of blood pressure can clear the neuroinflammation caused by blood pressure, re-duce the incidence of cerebrovascular accidents and hypertension, control the levels of diastolic and systolic blood pressure, and protect the blood brain barrier, which play a very important role in preventing and improving cognitive function. Therefore, controlling the dynamic balance of blood pressure is considered as a treatment and prevention measure for AD before, during and after clin-ical treatment. Regular blood pressure monitoring has a certain degree of promotion significance.
文章引用:许斯贤, 杨亿馨, 陈紫霞, 杨颖瑜, 王筠柠, 苏裕盛. 血压对阿尔茨海默病生理机制的影响研究[J]. 临床医学进展, 2022, 12(11): 10059-10066. https://doi.org/10.12677/ACM.2022.12111451

参考文献

[1] Gale, S.A., Acar, D. and Daffner, K.R. (2018) Dementia. The American Journal of Medicine, 131, 1161-1169. [Google Scholar] [CrossRef] [PubMed]
[2] Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chetelat, G., Teunissen, C.E., Cummings, J. and van der Flier, W.M. (2021) Alzheimer’s Disease. The Lancet, 397, 1577-1590. [Google Scholar] [CrossRef
[3] Knopman, D.S., Amieva, H., Petersen, R.C., Chetelat, G., Holtzman, D.M., Hyman, B.T., Nixon, R.A. and Jones, D.T. (2021) Alzheimer Disease. Nature Reviews Disease Primers, 7, Article No. 33. [Google Scholar] [CrossRef] [PubMed]
[4] Pasic, M.D., Diamandis, E.P., Mclaurin, J., Holtzman, D.M., Schmitt-Ulms, G. and Quirion, R. (2011) Alzheimer Disease: Advances in Pathogenesis, Diagnosis, and Therapy. Clini-cal Chemistry, 57, 664-669. [Google Scholar] [CrossRef] [PubMed]
[5] Tecalco-Cruz, A.C., Ramirez-Jarquin, J.O., Alvarez-Sanchez, M.E. and Zepeda-Cervantes, J. (2020) Epigenetic Basis of Alzheimer Disease. World Journal of Biological Chemistry, 11, 62-75. [Google Scholar] [CrossRef] [PubMed]
[6] Sanchez-Sarasua, S., Fernandez-Perez, I., Espi-nosa-Fernandez, V., Sanchez-Perez, A.M. and Ledesma, J.C. (2020) Can We Treat Neuroinflammation in Alzheimer’s Disease? International Journal of Molecular Sciences, 21, Article No. 8751. [Google Scholar] [CrossRef] [PubMed]
[7] (2022) 2022 Alzheimer’s Disease Facts and Figures. Alzheimer’s & Dementia, 18, 700-789. [Google Scholar] [CrossRef] [PubMed]
[8] Kapadia, A., Mirrahimi, A. and Dmytriw, A.A. (2020) Intersection between Sleep and Neurovascular Coupling as the Driving Pathophysiology of Alzheimer’s Disease. Medical Hypotheses, 144, Article ID: 110283. [Google Scholar] [CrossRef] [PubMed]
[9] Vaz, M. and Silvestre, S. (2020) Alzheimer’s Disease: Recent Treatment Strategies. European Journal of Pharmacology, 887, Article ID: 173554. [Google Scholar] [CrossRef] [PubMed]
[10] Gupta, G.L. and Samant, N.P. (2021) Current Druggable Targets for Therapeutic Control of Alzheimer’s Disease. Contemporary Clinical Trials, 109, Article ID: 106549. [Google Scholar] [CrossRef] [PubMed]
[11] Ansari, N. and Khodagholi, F. (2013) Molecular Mechanism Aspect of ER Stress in Alzheimer’s Disease: Current Approaches and Future Strategies. Current Drug Targets, 14, 114-122. [Google Scholar] [CrossRef] [PubMed]
[12] Mcdade, E.M. (2022) Alzheimer Disease. Continuum (Min-neap Minn), 28, 648-675. [Google Scholar] [CrossRef
[13] Cheng, X., Song, C., Du, Y., Gaur, U. and Yang, M. (2020) Pharmacological Treatment of Alzheimer’s Disease: Insights from Drosophila melanogaster. International Journal of Molecular Sciences, 21, Article No. 4621. [Google Scholar] [CrossRef] [PubMed]
[14] Norins, L.C. (2019) Predicted Economic Damage from a Quick, Simple Alzheimer’s Disease Cure. Medical Hypotheses, 133, Article ID: 109398. [Google Scholar] [CrossRef] [PubMed]
[15] Gregory, J., Vengalasetti, Y.V., Bredesen, D.E. and Rao, R.V. (2021) Neuroprotective Herbs for the Management of Alzheimer’s Disease. Biomolecules, 11, Article No. 543. [Google Scholar] [CrossRef] [PubMed]
[16] Ballard, C., Aarsland, D., Cummings, J., O’Brien, J., Mills, R., Molinuevo, J.L., Fladby, T., Williams, G., Doherty, P., Corbett, A. and Sultana, J. (2020) Drug Repositioning and Re-purposing for Alzheimer Disease. Nature Reviews Neurology, 16, 661-673. [Google Scholar] [CrossRef] [PubMed]
[17] Ou, Y.N., Yang, Y.X., Shen, X.N., Ma, Y.H., Chen, S.D., Dong, Q., Tan, L. and Yu, J.T. (2021) Genetically Determined Blood Pressure, Antihypertensive Medications, and Risk of Alzheimer’s Disease: A Mendelian Randomization Study. Alzheimer’s Research & Therapy, 13, Article No. 41. [Google Scholar] [CrossRef] [PubMed]
[18] Cheignon, C., Tomas, M., Bonnefont-Rousselot, D., Faller, P., Hureau, C. and Collin, F. (2018) Oxidative Stress and the Amyloid Beta Peptide in Alzheimer’s Disease. Redox Biology, 14, 450-464. [Google Scholar] [CrossRef] [PubMed]
[19] Yu, L., Petyuk, V.A., Tasaki, S., Boyle, P.A., Gaiteri, C., Schneider, J.A., De Jager, P.L. and Bennett, D.A. (2019) Association of Cortical Beta-Amyloid Protein in the Absence of Insoluble Deposits with Alzheimer Disease. JAMA Neurology, 76, 818-826. [Google Scholar] [CrossRef] [PubMed]
[20] Webers, A., Heneka, M.T. and Gleeson, P.A. (2020) The Role of Innate Immune Responses and Neuroinflammation in Amyloid Accumulation and Progression of Alzheimer’s Disease. Immunology & Cell Biology, 98, 28-41. [Google Scholar] [CrossRef] [PubMed]
[21] Eimer, W.A., Vijaya, K.D., Navalpur, S.N., et al. (2018) Alzheimer’s Disease-Associated Beta-Amyloid Is Rapidly Seeded by Herpesviridae to Protect against Brain Infection. Neuron, 99, 56-63. [Google Scholar] [CrossRef] [PubMed]
[22] Simic, G., Babic, L.M., Wray, S., et al. (2016) Tau Protein Hy-perphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules, 6, Article No. 6. [Google Scholar] [CrossRef] [PubMed]
[23] Guo, T., Noble, W. and Hanger, D.P. (2017) Roles of Tau Protein in Health and Disease. Acta Neuropathologica, 133, 665-704. [Google Scholar] [CrossRef] [PubMed]
[24] Hamano, T., Enomoto, S., Shirafuji, N., Ikawa, M., Yamamura, O., Yen, S.H. and Nakamoto, Y. (2021) Autophagy and Tau Protein. International Journal of Molecular Sciences, 22, Article No. 7475. [Google Scholar] [CrossRef] [PubMed]
[25] Goedert, M., Spillantini, M.G. and Crowther, R.A. (2015) A Brief History of Tau. Clinical Chemistry, 61, 1417-1418. [Google Scholar] [CrossRef] [PubMed]
[26] Rossi, B., Santos-Lima, B., Terrabuio, E., Zenaro, E. and Con-stantin, G. (2021) Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer’s Disease. Frontiers in Immunology, 12, Article ID: 639369. [Google Scholar] [CrossRef] [PubMed]
[27] Park, J., Baik, S.H., Mook-Jung, I., Irimia, D. and Cho, H. (2019) Mimicry of Central-Peripheral Immunity in Alzheimer’s Disease and Discovery of Neurodegenerative Roles in Neutro-phil. Frontiers in Immunology, 10, Article No. 2231. [Google Scholar] [CrossRef] [PubMed]
[28] Lim, B., Prassas, I. and Diamandis, E.P. (2021) Alzheimer Disease Pathogenesis: The Role of Autoimmunity. The Journal of Ap-plied Laboratory Medicine, 6, 756-764. [Google Scholar] [CrossRef] [PubMed]
[29] Bertholf, R.L. (2021) Is Alz-heimer Disease an Autoimmune Disorder? The Journal of Applied Laboratory Medicine, 6, 588-591. [Google Scholar] [CrossRef] [PubMed]
[30] Musicco, M., Palmer, K., Salamone, G., Lupo, F., Perri, R., Mosti, S., Spalletta, G., di Iulio, F., Pettenati, C., Cravello, L. and Caltagirone, C. (2009) Predictors of Progression of Cognitive Decline in Alzheimer’s Disease: The Role of Vascular and Sociodemographic Factors. Journal of Neurology, 256, 1288-1295. [Google Scholar] [CrossRef] [PubMed]
[31] Sproviero, W., Winchester, L., Newby, D., et al. (2021) High Blood Pressure and Risk of Dementia: A Two-Sample Mendelian Randomization Study in the UK Biobank. Biological Psychiatry, 89, 817-824. [Google Scholar] [CrossRef] [PubMed]
[32] Nasrallah, I.M., Pajewski, N.M., Auchus, A.P., et al. (2019) Association of Intensive vs Standard Blood Pressure Control with Cerebral White Matter Lesions. JAMA, 322, 524-534. [Google Scholar] [CrossRef] [PubMed]
[33] Takeuchi, H. and Kawashima, R. (2022) Effects of Diastolic Blood Pressure on Brain Structures and Cognitive Functions in Middle and Old Ages: Longitudinal Analyses. Nutrients, 14, Article No. 2464. [Google Scholar] [CrossRef] [PubMed]
[34] Harrison, J.K., Van Der Wardt, V., Conroy, S.P., et al. (2016) New Ho-rizons: The Management of Hypertension in People with Dementia. Age Ageing, 45, 740-746. [Google Scholar] [CrossRef] [PubMed]
[35] Walker, K.A., Sharrett, A.R., Wu, A., et al. (2019) Association of Mid-life to Late-Life Blood Pressure Patterns with Incident Dementia. JAMA, 322, 535-545. [Google Scholar] [CrossRef] [PubMed]
[36] Launer, L.J. (2019) Blood Pressure Control as an Intervention to Prevent Dementia. The Lancet Neurology, 18, 906-908. [Google Scholar] [CrossRef
[37] Thordardottir, S., Almkvist, O., Johansson, C., et al. (2020) Cerebrospinal Fluid ykl-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study. Journal of Alzheimer’s Disease, 76, 941-953. [Google Scholar] [CrossRef
[38] Hellwig, K., Kvartsberg, H., Portelius, E., et al. (2015) Neurogranin and ykl-40: Independent Markers of Synaptic Degeneration and Neuroinflammation in Alzheimer’s Disease. Alzheimer’s Research & Therapy, 7, Article No. 74. [Google Scholar] [CrossRef] [PubMed]
[39] Dhiman, K., Blennow, K., Zetterberg, H., Martins, R.N. and Gupta, V.B. (2019) Cerebrospinal Fluid Biomarkers for Understanding Multiple Aspects of Alzheimer’s Disease Patho-genesis. Cellular and Molecular Life Sciences, 76, 1833-1863. [Google Scholar] [CrossRef] [PubMed]
[40] Megur, A., Baltriukiene, D., Bukelskiene, V. and Burokas, A. (2020) The Microbiota-Gut-Brain Axis and Alzheimer’s Disease: Neuroinflammation Is to Blame? Nutrients, 13, Article No. 37. [Google Scholar] [CrossRef] [PubMed]
[41] Lopez-Arrieta, J.M. and Birks, J. (2000) Nimodipine for Primary Degenerative, Mixed and Vascular Dementia. Cochrane Database of Systematic Reviews, No. 3, D147. [Google Scholar] [CrossRef
[42] de Jonge, M.C. and Traber, J. (1993) Nimodipine: Cognition, Aging, and Degeneration. Clinical Neuropharmacology, 16, S25-S30. [Google Scholar] [CrossRef] [PubMed]
[43] Dobarro, M., Gerenu, G. and Ramirez, M.J. (2013) Propranolol Reduces Cognitive Deficits, Amyloid and Tau Pathology in Alzheimer’s Transgenic Mice. International Journal of Neuropsychopharmacology, 16, 2245-2257. [Google Scholar] [CrossRef
[44] Trigian, L.J., Royea, J., Lacalle-Aurioles, M., Tong, X.K. and Hamel, E. (2018) Pleiotropic Benefits of the Angiotensin Receptor Blocker Candesartan in a Mouse Model of Alzheimer Disease. Hypertension, 72, 1217-1226. [Google Scholar] [CrossRef
[45] de Oliveira, F.F., Bertolucci, P.H., Chen, E.S. and Smith, M.C. (2014) Brain-Penetrating Angiotensin-Converting Enzyme Inhibitors and Cognitive Change in Patients with Dementia Due to Alzheimer’s Disease. Journal of Alzheimer’s Disease, 42, S321-S324. [Google Scholar] [CrossRef
[46] Zhang, B., Li, W., Zhuo, Y., et al. (2021) L-3-n-butylphthalide Effec-tively Improves the Glymphatic Clearance and Reduce Amyloid-Beta Deposition in Alzheimer’s Transgenic Mice. Jour-nal of Molecular Neuroscience, 71, 1266-1274. [Google Scholar] [CrossRef] [PubMed]
[47] Morris, J.K., Vidoni, E.D., Johnson, D.K., et al. (2017) Aerobic Exercise for Alzheimer’s Disease: A Randomized Controlled Pilot Trial. PLOS ONE, 12, e170547. [Google Scholar] [CrossRef] [PubMed]
[48] Valenzuela, P.L., Castillo-Garcia, A., Morales, J.S., et al. (2020) Exercise Benefits on Alzheimer’s Disease: State-of-the-Science. Ageing Research Reviews, 62, Article ID: 101108. [Google Scholar] [CrossRef] [PubMed]
[49] Mcgrattan, A.M., Mcguinness, B., Mckinley, M.C., et al. (2019) Diet and Inflammation in Cognitive Ageing and Alzheimer’s Disease. Current Nutrition Reports, 8, 53-65. [Google Scholar] [CrossRef] [PubMed]
[50] Rusek, M., Pluta, R., Ulamek-Koziol, M. and Czuczwar, S.J. (2019) Ketogenic Diet in Alzheimer’s Disease. International Journal of Molecular Sciences, 20, Article No. 3892. [Google Scholar] [CrossRef] [PubMed]
[51] Broom, G.M., Shaw, I.C. and Rucklidge, J.J. (2019) The Ketogenic Di-et as a Potential Treatment and Prevention Strategy for Alzheimer’s Disease. Nutrition, 60, 118-121. [Google Scholar] [CrossRef] [PubMed]
[52] de Freitas, G.B., Lourenco, M.V. and De Felice, F.G. (2020) Pro-tective Actions of Exercise-Related fndc5/irisin in Memory and Alzheimer’s Disease. Journal of Neurochemistry, 155, 602-611. [Google Scholar] [CrossRef] [PubMed]